What is HFrecEF (Heart Failure with Recovered Ejection Fraction)?
HFrecEF is a distinct category of heart failure defined as patients who previously had a left ventricular ejection fraction (LVEF) ≤40%, subsequently achieved a ≥10% increase from baseline, and now have a follow-up LVEF >40%. 1
Definition and Diagnostic Criteria
The 2022 AHA/ACC/HFSA guidelines provide the working definition that distinguishes HFrecEF from other heart failure phenotypes 1. This represents patients who have transitioned from HFrEF (LVEF ≤40%) to an improved ejection fraction category, but importantly, this does not mean complete myocardial recovery or normalization of left ventricular function 1.
Key diagnostic requirements:
- Baseline LVEF ≤40% (documented HFrEF)
- ≥10% absolute increase in LVEF from baseline
- Follow-up LVEF >40% on repeat measurement 1
Clinical Significance and Prognosis
HFrecEF patients represent approximately 12-16% of heart failure populations 2 and have distinct characteristics:
Better outcomes than persistent HFrEF:
- Lowest all-cause mortality compared to both HFrEF and HFpEF 2
- Lower cardiovascular mortality 2
- Improved quality of life, with each 10% increase in LVEF associated with a 4.8-point improvement in Kansas City Cardiomyopathy Questionnaire scores 3
- Reduced rehospitalization rates 4
However, incomplete recovery persists:
- Mortality and morbidity remain higher than the normal population 4
- Cardiac structural abnormalities persist (LV chamber dilatation, ventricular systolic and diastolic dysfunction) 1
- Microscopic changes continue: cardiomyocyte morphological changes, extracellular matrix deposition, and abnormal gene expression 5
- Risk of re-deterioration and recurrence of HFrEF remains 5, 6
Predictors of LVEF Recovery
Independent factors predicting recovery to HFrecEF status: 2
- Left ventricular end-diastolic diameter ≤55 mm (strongest predictor, OR 5.9)
- Higher diastolic blood pressure (OR 1.06 per mmHg)
- Faster resting heart rate (OR 1.04 per beat)
- Absence of old myocardial infarction (OR 5.3)
Patient characteristics associated with HFrecEF: 2
- Younger age
- More likely female
- Higher systolic and diastolic blood pressure
- Dilated cardiomyopathy more common than ischemic etiology
Critical Clinical Pitfalls
Do not assume complete recovery: Despite improved LVEF, these patients maintain pathological changes at the cellular level and remain at risk for adverse outcomes 1, 5. The term "recovered" refers to ejection fraction improvement, not complete myocardial healing.
Continued arrhythmia risk: There is an appreciable ongoing risk of ventricular arrhythmias even after LVEF recovery, which has implications for ICD management decisions 6.
Lack of specific treatment guidelines: Current evidence for managing HFrecEF is limited, with no dedicated clinical trial data to guide therapy 5, 4. Most clinicians continue guideline-directed medical therapy despite improved LVEF, though optimal duration and intensity remain undefined.
Distinguishing HFrecEF from Other Categories
- HFrEF: LVEF ≤40% (persistent reduction) 7
- HFmrEF: LVEF 40-49% (mid-range, but without documented prior reduction) 7
- HFpEF: LVEF >40% (preserved, but without documented prior reduction) 7
- HFrecEF: Previously ≤40%, now >40% with ≥10% improvement 1
The distinction matters because HFrecEF patients have different underlying pathophysiology, treatment responses, and prognoses compared to patients who never had reduced ejection fraction 4.